Completed PHASE3 INTERVENTIONAL 1-arm NCT01811667

Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations (vasca-LM)

Clinical Study on Efficacy and Safety of the mTor Rapamycin Inhibitor Found in the Complex Vascular Malformations

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Interventions Sirolimus

Updated 5 times since 2017 Last updated: Apr 13, 2016 Started: May 31, 2012 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cardiovascular Abnormalities and is currently completed. Cliniques universitaires Saint-Luc- Université Catholique de Louvain leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Data source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brussels, Belgium